Field Trip Health Ltd.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Full Time Employees
- 194
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 30 Duncan Street Toronto ON Canada M5V 2C3
- IPO Date
- Oct 6, 2020
- CIK
- 0001865482
- Website
- fieldtriphealth.com
- Similar Companies
- Business
- Field Trip Health Ltd. (CSE: FTRP) operates as a provider of psychedelic-assisted psychotherapy and mental health treatments, focusing on ketamine-enhanced programs for conditions including depression, anxiety, PTSD, and chronic pain. The company delivers clinician-supervised in-person and at-home services such as ketamine-assisted psychotherapy, stellate ganglion block via Dual Sympathetic Reset (DSR) protocol, transcranial magnetic stimulation (TMS), structured psychotherapy, and self-guided digital tools through its proprietary app featuring music, meditations, and mindfulness resources; it targets adults with treatment-resistant mental health issues who have not achieved sufficient relief from conventional therapies or medications. Field Trip Health maintains clinics across Canada in cities including Toronto, Vancouver, Ottawa, Montreal, Hamilton, Kitchener-Waterloo, Thunder Bay, and Sault Ste. Marie, alongside U.S. locations in New York and Washington, D.C., founded in 2019 and headquartered in Toronto, Ontario. In June 2023, its U.S. assets—including clinics, outcome data, research, technology stack, and key leadership—were acquired by Stella, a trauma care provider, enhancing Stella's offerings while Field Trip Health continues Canadian operations and plans expansion of DSR treatments; earlier, in May 2022, the company underwent a corporate split, separating its drug discovery division into Reunion Neuroscience Inc., and it listed on Nasdaq under FTRP in July 2021 following prior CSE listing and a C$95 million financing round in March 2021.
Field Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q1 2023 Results - Earnings Call Transcript
Field Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q4 2022 Results - Earnings Call Transcript
Earnings Previews: Constellation Brands, Field Trip Health, NovaGold, Walgreens
Field Trip Health Ltd. to Present at the H.C.
Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2022 Results Conference Call for Thursday, June 30, 2022 at 8:30 AM ET
Field Trip Health Ltd. to Participate in Upcoming Investor Conferences in May 2022
Field Trip Health Ltd. to Participate in Upcoming Investor Conferences
Field Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q3 2022 - Earnings Call Transcript
Field Trip Health Posts 330% YoY Increase In Q3 Revenue
Cybin, MindMed, and Field Trip Health Headline PSYC's First CEO Round Table Event
Field Trip Health Ltd. Schedules Third Fiscal Quarter 2022 Financial Results Conference Call for February 16, 2022 at 8:30 AM ET
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
Field Trip Health Ltd. to Participate in H.C.
3 Psychedelic Stocks to Play the Shroom Boom
9 Psychedelic Stocks to Watch For 2022
Field Trip Health Ltd. to Participate in Upcoming Conferences in December 2021
3 Psychedelic Stocks for Potential Out-of-This-World Gains
Field Trip Health Ltd.'s (FTRP) CEO Joseph del Moral on Q2 2022 Results - Earnings Call Transcript
Field Trip Health Ltd. to Participate in Upcoming Conferences in November 2021
Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, November 16, 2021 at 8:30 AM ET